Retatrutide 40 mg — highest-strength research vial

Regulatory positioning: Clinical trial supply only. Retatrutide is a patented Eli Lilly triple-agonist molecule (LY3437943). Not approved in any jurisdiction as of 2026. Supplied for research and clinical trial supply only — not for commercial distribution in jurisdictions where patent protection is active. Subject to buyer compliance with applicable patent law in the destination jurisdiction.

Overview

Retatrutide 40 mg is the highest-strength research vial format of the synthetic triple-agonist research peptide that engages GIP, GLP-1, and glucagon receptor pathways in a single molecule. The 40 mg format is the bulk SKU for distributors and laboratories running high-mass analytical method development, large-scale cell-based screening campaigns, and reference-standard stock programmes that require substantial quantities of the same lot. SPK Pharma India supplies Retatrutide 40 mg as a documented, lot-traceable research compound for distributors, contract manufacturers, and academic laboratories, with the full triple-agonist sequence disclosed on the lot-matched Certificate of Analysis. The product is supplied for research and analytical applications only.

Specifications

Research context

The 40 mg vial format is positioned as the bulk research SKU in the Retatrutide tier programme. It is intended for laboratories and distributors with established triple-agonist research programmes that have validated their assay at lower vial formats and now need the same lot at scale. Typical applications include large-scale cell-based screening across multiple receptor cell lines, multi-arm study designs that compare single-, dual-, and triple-agonist peptides in parallel, and stability-indicating method development where the same lot is referenced across multiple analytical timepoints.

The triple-agonist mechanism — simultaneous engagement of GIP, GLP-1, and glucagon receptors — remains the central research question, and the 40 mg format supports the kind of study scale where the receptor-engagement and downstream signalling profiles can be characterised comprehensively across multiple pathways in parallel. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are CAS 2381089-83-2, the 39-amino-acid backbone, the approximate molecular weight, the lyophilized powder form, and the documented purity threshold (≥99% HPLC). The full amino acid sequence is disclosed on the lot-matched COA and on the product specification sheet.

Packaging and supply

• 40 mg research vial — the highest-strength research format in the Retatrutide tier programme, suitable for large-scale screening, multi-arm comparative studies, and recurring reference-standard programmes. Standard MOQ: 2 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders across the 10 mg / 20 mg / 30 mg / 40 mg tiered formats.

Distributor pricing is available on application, with volume tiers structured across the 10/20/30/40 mg formats. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks.

Quality and documentation

Every lot of Retatrutide 40 mg ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• For longer peptides, avoid vigorous vortexing; allow gentle dissolution to minimise aggregation.

Shipping

Retatrutide 40 mg is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

Retatrutide is a patented Eli Lilly triple-agonist molecule (LY3437943). Not approved in any jurisdiction as of 2026. Supplied for research and clinical trial supply only — not for commercial distribution in jurisdictions where patent protection is active. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction, for compliance with applicable patent law, and for ensuring that downstream handling is consistent with the regulatory positioning stated above.

Lead form CTA

To request a wholesale quote for Retatrutide 40 mg, contact the trade desk with the subject line "Retatrutide 40 mg wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• Retatrutide 10 mg — standard research vial format
• Retatrutide 20 mg — concentrated research vial format
• Retatrutide 30 mg — bulk research vial format
• Cagrilintide — long-chain amylin analogue research peptide
• 5-Amino-1MQ — small-molecule NNMT inhibitor scaffold